AiNEX is Mycenax’s bevacizumab, the biosimilar version of Avastin®, and the humanized monoclonal antibody IgG1 targeted the vascular endothelial growth factor, VEGF. Through binding VEGF, it inhibits angiogenesis and tumor growth.
Bevacizumab is indicated for metastatic coloreactal cancer, non-small cell lung cancer, metastatic breast cancer, glioblastoma, metastatic renal cancer, ovarian cancer and metastatic cervical cancer.
The development of AiNEX is partnered with a European pharmaceutical. AiNEX has shown its high biosimilarilty to its reference product. Next, the up-scaling to 500L bioreactor process and full comparability study will be completed by 2015.